The risk of developing a blood clot after having COVID-19 is eight times higher than after being given the Oxford-AstraZeneca jab, according to a study by Oxford University.
Cerebral venous thrombosis (CVT) occurred in 39 in a million COVID-19 patients, compared with about five in a million people given the AstraZeneca vaccine.
In the study of over 500,000 coronavirus patients, the risk was reported to be around 100 times higher than normal after infection.
Numerous countries have limited use of the vaccine to certain age groups or paused its rollout – with Denmark even dropping the jab from its vaccination programme permanently – following reports of very rare cases of blood clots.
However, the Oxford study suggested around a third (30 percent) of the CVT reports after COVID-19 infection were in people under 30.